| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-07 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.15 | 3e-07 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.17 | 6e-07 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.16 | 1e-06 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.14 | 5e-06 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.15 | 7e-06 |